Cumberland Pharmaceuticals Inc. (CPIX)
Market Cap | 31.88M |
Revenue (ttm) | 36.79M |
Net Income (ttm) | -10.87M |
Shares Out | 14.04M |
EPS (ttm) | -0.77 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 188,828 |
Open | 2.350 |
Previous Close | 2.320 |
Day's Range | 2.250 - 2.388 |
52-Week Range | 1.040 - 3.050 |
Beta | 0.29 |
Analysts | n/a |
Price Target | n/a |
Earnings Date | Nov 7, 2024 |
About CPIX
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infect... [Read more]
Financial Performance
In 2023, CPIX's revenue was $39.55 million, a decrease of -5.85% compared to the previous year's $42.01 million. Losses were -$6.28 million, 12.7% more than in 2022.
Financial StatementsNews
Why Is Cumberland Pharmaceuticals Stock Trading Over 100% on Tuesday?
On Monday, the FDA approved Cumberland Pharmaceuticals Inc's CPIX supplemental New Drug Application (sNDA) for its Acetadote (N-acetylcysteine for injection) product.
FDA APPROVES ACETADOTE® sNDA
- New Dosing Regimen Simplifies Administration - NASHVILLE, Tenn. , Dec. 9, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on deliver...
Cumberland Pharmaceuticals Inc. (CPIX) Q3 2024 Earnings Call Transcript
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Molly Aggas - Investor Relations, Dalton Agency A.J. Kazimi - Chief Exe...
Cumberland Pharmaceuticals Reports Third Quarter 2024 Financial Results and Company Update
– New Real World Study of 150,000 Patients Favors Caldolor over ketorolac – – DMD Program Receives FDA Orphan Drug & Rare Pediatric Disease Designations – NASHVILLE, Tenn. , Nov. 7, ...
CUMBERLAND PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG AND RARE PEDIATRIC DISEASE DESIGNATIONS FOR NEW TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY
NASHVILLE, Tenn. , Nov. 6, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, announced today that the United States (U.S.) Food and Drug Administ...
New Study Compares Caldolor® (ibuprofen injection) to ketorolac
– Real World Study Compared Over 150,000 Adult & Pediatric Patients – – Caldolor Associated with Fewer Adverse Drug Reactions – – Caldolor also Improved Healthcare Utilization – N...
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE THIRD QUARTER 2024 FINANCIAL RESULTS
NASHVILLE, Tenn. , Oct. 31, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that it will release its third quarter 2024 financi...
Cumberland Pharmaceuticals Inc. (CPIX) Q2 2024 Earnings Call Transcript
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Q2 2024 Results Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Molly Aggas - Investor Relations, Dalton Agency A.J. Kazimi - Chi...
Cumberland Pharmaceuticals Reports 16% Sequential Revenue Growth in Second Quarter 2024
NASHVILLE, Tenn. , Aug. 6, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, today announced significantly improved financial results and a favor...
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE SECOND QUARTER 2024 FINANCIAL RESULTS
NASHVILLE, Tenn. , July 30, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that it will release its second quarter 2024 financ...
Cumberland Pharmaceuticals Inc. (CPIX) Q1 2024 Earnings Call Transcript
Start Time: 15:30 January 1, 0000 3:59 PM ET Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Q1 2024 Earnings Conference Call May 07, 2024, 15:30 PM ET Company Participants A.J. Kazimi - CEO Todd Antho...
Cumberland Pharmaceuticals Reports First Quarter 2024 Financial Results & Company Update
NASHVILLE, TENN., May 7, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, today announced that its product portfolio of FDA-approved brands deli...
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE FIRST QUARTER 2024 FINANCIAL RESULTS
NASHVILLE, Tenn. , April 30, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that it will release its first quarter 2024 financ...
NEW REPORT SUPPORTS USE OF CALDOLOR® AS A STANDARD OF CARE ACROSS PATIENT POPULATIONS
Growing data shows intravenous ibuprofen is safe and effective for the treatment of pain and fever in adults, children and infants NASHVILLE, Tenn. , April 2, 2024 /PRNewswire/ -- Cumberland Pharmaceu...
Cumberland Pharmaceuticals Inc. (CPIX) Q4 2023 Earnings Call Transcript
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Q4 2023 Earnings Conference Call March 5, 2024 4:30 PM ET Company Participants Molly Aggas - Account Supervisor, Dalton Agency A. J. Kazimi - Chairman an...
Cumberland Pharmaceuticals Reports Annual 2023 Financial Results
2023 highlights include expanded FDA approval and new study publications NASHVILLE, Tenn. , March 5, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical com...
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2023 FINANCIAL RESULTS
NASHVILLE, Tenn. , Feb. 27, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceuticals company, announced today that it will release its annual 2023 financial res...
Cumberland Pharmaceuticals Inc. (CPIX) Q3 2023 Earnings Call Transcript
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Q3 2023 Earnings Conference Call November 7, 2023 4:30 PM ET Company Participants Molly Aggas - Account Supervisor, Dalton Agency A. J. Kazimi - Chairman...
Cumberland Pharmaceuticals Reports Third Quarter 2023 Financial Results
NASHVILLE, Tenn. , Nov. 7, 2023 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands de...
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE THIRD QUARTER 2023 FINANCIAL RESULTS
NASHVILLE, Tenn., Oct. 31, 2023 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceuticals company, announced today that it will release the third quarter 2023 financi...
NEW VIBATV® PEDIATRIC PUBLICATION HIGHLIGHTS ITS SAFETY IN PATIENTS 2 TO 17 YEARS OF AGE
NASHVILLE, Tenn. , Oct. 10, 2023 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today a new publication in Antimicrobial Agents and Chemotherapy 1 detailing the results of th...
Cumberland Pharmaceuticals Inc. (CPIX) Q2 2023 Earnings Call Transcript
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Q2 2023 Earnings Conference Call August 8, 2023 4:30 PM ET Company Participants Molly Aggas - IR A.J. Kazimi - CEO Todd Anthony - VP, Organizational Deve...
Cumberland Pharmaceuticals Reports Revenue and Earnings Growth Second Quarter 2023
NASHVILLE, Tenn. , Aug. 8, 2023 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today announced significantly improved financial results and a favor...
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE SECOND QUARTER 2023 FINANCIAL RESULTS
NASHVILLE, Tenn. , Aug. 1, 2023 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceuticals company, announced today that it will release the second quarter 2023 financ...
NEW PUBLICATION SUPPORTS THE USE OF CALDOLOR® IN NEWBORN PEDIATRIC PATIENTS
NASHVILLE, Tenn. , June 26, 2023 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today announced the publication of positive results from a clinical...